Format

Send to:

Choose Destination
See comment in PubMed Commons below
Semin Radiat Oncol. 2014 Apr;24(2):77-84. doi: 10.1016/j.semradonc.2013.11.005.

Intraductal papillary mucinous neoplasm: clinical surveillance and management decisions.

Author information

  • 1Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
  • 2Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
  • 3Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA. Electronic address: tshong1@partners.org.

Abstract

Intraductal papillary mucinous neoplasm (IPMN) of the pancreas is a relatively rare cystic neoplasm. Although most IPMNs appear to be benign and may be managed by surveillance, all IPMNs are considered premalignant lesions with malignant potential. As such, current efforts are focused on identifying those neoplasms that are at high risk for malignancy to optimize treatment strategy and outcome. IPMNs with invasive carcinoma have clinical outcomes that approach those of conventional pancreatic ductal adenocarcinoma. Management guidelines recommend surgical resection for IPMNs with high-risk imaging or cytologic features. The role of adjuvant therapy is unclear, and we review the evidence for chemoradiation here. Some studies suggest adjuvant chemoradiation may have the greatest impact in malignant IPMNs with adverse histologic features, that is, lymph node metastasis at the time of diagnosis or positive surgical margins. As more IPMNs are recognized and treated, more evidence will accumulate to guide clinicians regarding appropriate use of radiotherapy in the management of IPMN.

© 2013 Published by Elsevier Inc.

PMID:
24635864
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk